Psychiatry and Clinical Psychopharmacology
Review Article

Inflammation, Insulin Resistance and the Pathophysiology of Depression: Implications for Novel Antidepressant Developments

1.

Department of Pharmacology and Therapeutics,National University of Ireland, Galway

2.

Department of Pharmacology and Psychopharmacology Research Unit University of Marmara, Istanbul, Turkey

Psychiatry and Clinical Psychopharmacology 2020; 30: 71-80
DOI: 10.5455/PCP.20200215032026
Read: 588 Downloads: 315 Published: 19 January 2021

This review summarises the impact of chronic low grade inflammation as a causative factor in the pathophysiology of major depression. Evidence is presented to show that proinflammatory cytokines both directly, and indirectly by increasing hypercortisolaemia, desensitise insulin receptors and thereby decrease the transport of glucose into the brain (the diabetic brain). In addition, the proinflammatory cytokines activate the tryptophan-kynurenine pathway which results in the synthesis of the NMDAglutamate receptor agonist quinolinic acid. This acts as a neurotoxin and facilitates neuronal apoptosis. As metabolic changes initiated by low grade inflammation underlie the pathophysiology of depression, drugs which attenuate the inflammatory cascade may present an approach to the novel development of antidepressants. The review concludes with a summary of drugs which might be considered for their novel therapeutic activity. Key points are; i)Chronic low grade inflammation commonly occurs in major depression and contributes to adverse changes in brain energy metabolism by decreasing insulin receptor function and thereby reducing glucose transport into the brain. ii) Low grade inflammation initiates an increase in the tryptophan-kynurenine pathway which enhances the NMDA-glutamate receptor function and thereby increases neuronal apoptosis, iii) As many of the pathophysiological changes in depression result from dysfunctional brain metabolism caused by chronic low grade inflammation, it is concluded that drugs targeting the inflammatory pathways may offer new possibilities for the development of novel antidepressants.

To cite this article: Leonard BE, Aricioglu F. Inflammation, Insulin Resistance and the Pathophysiology of Depression: Implications for Novel Antidepressant Developments.Psychiatry and Clinical Psychopharmacology 2020;30(1):71-80

Files
EISSN 2475-0581